DailyMed lists Structured Product Labeling version 12 for the reviewed Abaloparatide label family with a published date of 2022-12-28. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 4 for the reviewed Tesamorelin label family with a published date of 2022-12-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 216445 with status AP dated 2022-12-23, and names daptomycin among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 47 for the reviewed Dulaglutide label family with a published date of 2022-12-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 30 for the reviewed Linaclotide label family with a published date of 2022-12-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 46 for the reviewed Dulaglutide label family with a published date of 2022-11-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2022-25549, attributed to FDA and its parent HHS department, on 2022-11-23. Its official title is “List of Bulk Drug Substances for Which There is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” and PeptideScanner's exact reviewed identity mapping connects the document to Lutetium Lu 177 dotatate.
The Federal Register published notice 2022-25210, attributed to FDA and its parent HHS department, on 2022-11-18. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon and Goserelin.
The official Drugs@FDA dataset lists original submission 1 for ANDA 216922 with status AP dated 2022-11-16, and names desmopressin acetate among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 2 for the reviewed Semaglutide label family with a published date of 2022-11-11. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 11 for the reviewed Abaloparatide label family with a published date of 2022-11-10. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 4 for the reviewed Leuprolide label family with a published date of 2022-11-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 215336 with status AP dated 2022-10-28, and names leuprolide acetate among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 3 for the reviewed Ziconotide label family with a published date of 2022-10-27. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 13 for the reviewed Pramlintide label family with a published date of 2022-10-21. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 216413 with status AP dated 2022-09-23, and names daptomycin among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for NDA 022231 with status AP dated 2022-09-14, and names terlipressin acetate among the application record's active ingredients.
The Federal Register published notice 2022-19155, attributed to FDA and its parent HHS department, on 2022-09-06. Its official title is “Issuance of Priority Review Voucher; Rare Pediatric Disease Product,” and PeptideScanner's exact reviewed identity mapping connects the document to Vosoritide.
The Federal Register published notice 2022-18523, attributed to FDA and its parent HHS department, on 2022-08-29. Its official title is “Notice of Approval of Product Under Voucher: Material Threat Medical Countermeasure Priority Review Voucher,” and PeptideScanner's exact reviewed identity mapping connects the document to Tirzepatide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 215961 with status AP dated 2022-08-19, and names desmopressin acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 215890 with status AP dated 2022-08-18, and names daptomycin among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 214314 with status AP dated 2022-08-15, and names vasopressin among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 215737 with status AP dated 2022-08-12, and names cetrorelix acetate among the application record's active ingredients.
The Federal Register published notice 2022-17056, attributed to FDA and its parent HHS department, on 2022-08-09. Its official title is “Determination That AVC (Sulfanilamide) Vaginal Cream, 15%, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Eptifibatide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 212944 with status AP dated 2022-08-05, and names vasopressin among the application record's active ingredients.
The Federal Register published notice 2022-16502, attributed to FDA and its parent HHS department, on 2022-08-03. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Setmelanotide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 211857 with status AP dated 2022-07-18, and names vasopressin among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 5 for the reviewed Setmelanotide label family with a published date of 2022-07-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2022-14134, attributed to FDA and its parent HHS department, on 2022-07-01. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; IMCIVREE,” and PeptideScanner's exact reviewed identity mapping connects the document to Setmelanotide.
DailyMed lists Structured Product Labeling version 45 for the reviewed Dulaglutide label family with a published date of 2022-06-20. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 17 for the reviewed Lixisenatide label family with a published date of 2022-06-20. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 214996 with status AP dated 2022-06-06, and names ganirelix acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 212963 with status AP dated 2022-06-06, and names leuprolide acetate among the application record's active ingredients.
The Federal Register published notice 2022-10701, attributed to FDA and its parent HHS department, on 2022-05-20. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide and Linaclotide.
The official Drugs@FDA dataset lists original submission 1 for NDA 215866 with status AP dated 2022-05-13, and names tirzepatide among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 4 for the reviewed Setmelanotide label family with a published date of 2022-04-27. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 3 for the reviewed Setmelanotide label family with a published date of 2022-04-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 212613 with status AP dated 2022-04-07, and names ganirelix acetate among the application record's active ingredients.
The Federal Register published notice 2022-03248, attributed to FDA and its parent HHS department, on 2022-02-18. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.
DailyMed lists Structured Product Labeling version 42 for the reviewed Dulaglutide label family with a published date of 2022-02-15. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2022-01693, attributed to FDA and its parent HHS department, on 2022-01-28. Its official title is “21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.
The official Drugs@FDA dataset lists original submission 1 for NDA 213645 with status AP dated 2022-01-25, and names daptomycin among the application record's active ingredients.